Grifols | GRFS - Net Income


Grifols reported EUR148.4M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Alaunos Therapeutics USD -1.16M 417K Sep/2025
Arca Biopharma USD -21M 4.78M Mar/2025
aTyr Pharma USD -25.74M 6.21M Sep/2025
Bio Path USD -2.85M 99K Mar/2025
Brainstorm Cell Therapeutics USD -2.86M 109K Mar/2025
Capricor Therapeutics USD -24.39M 17.27M Mar/2025
Cara Therapeutics USD -4.91M 2.77M Mar/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Grifols EUR 148.4M 15.76M Sep/2025
Immunic USD -24.37M 2.99M Sep/2024
Infinity Pharmaceuticals USD -9.96M 1.09M Jun/2023
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
TherapeuticsMD USD -1.09M 356K Jun/2024